Polymerase News and Research

RSS

An analysis of SARS-CoV-2 breakthrough infections by variant and vaccine

Researchers compared the distribution of SARS-CoV-2 genotypes to the prevalence of SARS-CoV-2 variants.

28 Nov 2021

Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients

Researchers conducted a Phase II randomized placebo-controlled, double-blinded trial between July 8, 2020, and March 23. 2021.

28 Nov 2021

How often does SARS-CoV-2 infect alongside another viruses?

Researchers have been exploring data from COVID-19 patients tested at hospitals or clinics that also look for evidence of other diseases.

28 Nov 2021

The introduction and rapid spread of SARS-CoV-2 Gamma in Venezuela

Researchers from the Instituto Venezolano de Investigaciones Científica investigate the introduction of one of the VOCs into Venezuela.

28 Nov 2021

Prediction of severe infection based on SARS-CoV-2 genomic analysis

A group of researchers have used these SARS-CoV-2 sequence data and developed an algorithm to predict severity based upon viral mutations.

26 Nov 2021

Antiviral activity of a photoactivable natural product on coronaviruses

A new study showed that pheophorbide a has antiviral activity against many CoVs.

26 Nov 2021

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

25 Nov 2021

Study explores adverse effects of SARS-CoV-2-induced antibody responses

The authors of a research paper published in the journal Frontiers in Immunology used Sandwich ELISA tests to determine the distribution of IgG sub-classes and complement activation levels in plasma from convalescent individuals.

25 Nov 2021

Using metal nanoparticles to fight SARS-CoV-2

A recent review article looks at the potential of nanotechnology in fighting severe acute respiratory syndrome 2 (SARS-CoV-2), with several possibilities of strategies in therapeutics, vaccines, and prevention.

25 Nov 2021

Study demonstrates effectiveness of two doses of BBV152 vaccine against COVID-19

In a study published in The Lancet Infectious Diseases, researchers investigated the effectiveness of the BBV152 vaccine among employees of the All India Institute of Medical Sciences.

25 Nov 2021

Breakthrough infections from SARS-CoV-2 Delta variant among vaccinated healthcare workers

A new study published on the medRxiv* preprint server employed in-silico techniques, combining genomic and epidemiological data, to determine possible Delta-variant transmission events between vaccinated healthcare workers (HCWs) in Indian hospitals.

25 Nov 2021

Serum SARS-CoV-2 antigen: A better predictor of COVID-19 severity

In this perspective, a new study published on the medRxiv* preprint server analyzed the clinical efficacy of two serum antigen tests to identify SARS CoV-2 infection and evaluate the kinetics of serum nucleocapsid (N) antigen in severe and non-severe patients for disease severity prediction.

24 Nov 2021

Can dexamethasone reduce prolonged COVID-19 symptoms?

A new study assesses hospitalized patients after recovering from COVID-19 by comparing the individuals before and after being treated with dexamethasone.

24 Nov 2021

Healthcare workers at increased SARS-CoV-2 infection risk during second wave

A new study evaluates the SARS-CoV-2 infection rates among healthcare workers during the second wave of the COVID-19 pandemic.

24 Nov 2021

Markers of SARS-CoV-2 shedding in vaccinated and unvaccinated individuals

The study uses serial mid-turbinate nasal specimens collected from a subset of incarcerated persons infected during this outbreak.

24 Nov 2021

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

In this study, published on the medRxiv* preprint server, the humoral response to SARS-CoV-2 was assessed before and after three months of administration of the BNT162b2 mRNA COVID-19 vaccination (Pfizer-BioNTech). In addition, elders' humoral responses were compared to those of a younger group, and a functional neutralization experiment against the Wuhan-Hu-1 (WH1) virus and the Delta variant was carried out.

23 Nov 2021